Our model’s fair value is , about below today’s price.
Kura Oncology (KURA) stock
Know the moment the smart money buys or sells Kura Oncology.
See who owns Kura Oncology, what its own executives are doing with their shares and what social media is saying, with an alert the moment any of it changes.
- Every stock, fund, option and crypto you own, in one place.
- News, fundamentals and technicals, explained by AI in plain English.
- Congress, top fund managers, insiders, analysts and social media signals, with an alert the moment they move.
No credit card30 days of Pro free
Instaport’s take on Kura Oncology
- Momentum
- Revisions
- Profitability
- Growth
- Valuation
Kura Oncology is down 35% over the past year, behind the S&P 500’s 12% gain.
No credit card30 days of Pro free
Never be the last to know
When a top fund, Congress or Kura Oncology’s own executives buy or sell, you hear about it the day it goes public, not weeks later in the news.
Hours and days of research in minutes
Congress, top fund managers, insiders, analysts and social media, on every stock you own, in one glance. No more checking five websites.
Invest with confidence
AI explains what each move means for your portfolio in plain English, so you know what you own and why.
Kura Oncology at a glance
Who owns Kura Oncology
Top fund managers
| Fund · manager | % of their portfolio | Value |
|---|---|---|
| 1.97% | $84.61M | |
| 0.03% | $21.48M | |
| 0.01% | $39.51M |
Kura Oncology’s executives: 12 sales and 4 open-market buys in their last 18 reported trades.
9 top funds and 0 members of Congress own Kura Oncology. See them all free →
Kura Oncology (KURA): funds that hold it
| # | Fund | % of fund |
|---|---|---|
| 1 | BBPVirtus Biotech ETF | 1.37% |
| 2 | CANCTema Oncology ETF | 1.03% |
| 3 | IDNAiShares Genomics Immunology and Healthcare ETF | 0.88% |
| 4 | SBIOALPS Medical Breakthroughs ETF | 0.58% |
| 5 | XBIState Street SPDR S&P Biotech ETF | 0.32% |
| 6 | HAPSHarbor Human Capital Factor US Small Cap ETF | 0.31% |
| 7 | LABUDirexion Daily S&P Biotech Bull 3X ETF | 0.19% |
| 8 | RFLRInnovator U.S. Small Cap Managed Floor ETF | 0.13% |
| 9 | FSEGFidelity Enhanced Small Cap Growth ETF | 0.11% |
| 10 | SMMViShares MSCI USA Small-Cap Min Vol Factor ETF | 0.10% |
Questions about Kura Oncology stock
Is Kura Oncology stock overvalued?
Instaport’s fair value model currently rates Kura Oncology as overvalued compared with the cash it is expected to generate. Create a free account to see the fair value estimate and the range behind it.
Which top fund managers own Kura Oncology stock?
Aaron Cowen’s Suvretta Capital holds KURA, about 2% of its portfolio (roughly $84.6M) as of its latest filing. Peter Brown’s Renaissance Technologies and Cliff Asness’s AQR Capital Management are also large holders.
Are Kura Oncology insiders buying or selling?
Mostly selling. Kura Oncology insiders made 12 sales and 4 open-market buys in their last 18 reported transactions.
Power your portfolio with AI.
Know what’s moving your investments in minutes, so you can invest better.
Sign up freeNo credit card30 days of Pro free
Also on Instaport:Free stock portfolio tracker
Information and analytics, not investment advice.